Pharmacokinetics and biodistribution of surface modification polymeric nanoparticles

Archives of Pharmacal Research

Volumn 31, Issue 4, 2008, Pages 547-554

  Liu, Mingxing ^a,b   Li, Huifang ^b,c   Luo, Guoan ^b   Liu, Qingfei ^b   Wang, Yiming ^b  

^a HUBEI UNIVERSITY OF TECHNOLOGY   (China)

^b TSINGHUA UNIVERSITY   (China)

^c JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Biodistribution; Breviscapine; Nanoparticles; Pharmacokinetics; Poloxamer 188; Poly(D, L lactic acid)

Indexed keywords

BREVISCAPINE; DRUG CARRIER; FLAVONOID; HERBACEOUS AGENT; LACTIC ACID; NANOPARTICLE; POLYLACTIC ACID; POLYMER;

ANIMAL; ARTICLE; BLOOD BRAIN BARRIER; CHEMISTRY; COMPARATIVE STUDY; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; METHODOLOGY; PARTICLE SIZE; PERMEABILITY; PHARMACEUTICS; RAT; RETICULOENDOTHELIAL SYSTEM; SOLUBILITY; SPECTROSCOPY; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; BLOOD-BRAIN BARRIER; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG COMPOUNDING; DRUGS, CHINESE HERBAL; FLAVONOIDS; INJECTIONS, INTRAVENOUS; LACTIC ACID; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MONONUCLEAR PHAGOCYTE SYSTEM; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SPECTRUM ANALYSIS; TECHNOLOGY, PHARMACEUTICAL; TISSUE DISTRIBUTION;

EID: 43049133246     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-001-1191-8     Document Type: Article

References (31)

1. Alvarez-Roman, R., Naik, A., Kalia, Y. N., Guy, R. H., and Fessi, H., Enhancement of topical delivery from biodegradable nanoparticles. Pharm. Res., 21, 1818-1825 (2004).
2. Cui, J. M. and Wu, S., The advance on the research of breviscapine (in chinese). Natural Product Res. Develop., 15, 225-229 (2003).
3. Dunn, S. E., Coombes, A. G. A., Garnett, M. C., Davis, S. S., Davies, M. C., and Illum, L., In vitro cell interaction and in vivo biodistribution of poly(lactide-co-glycolide) nanospheres surface modified by poloxamer and poloxamine copolymers. J. Control. Release, 44, 65-76 (1997).
4. Elizabeth, C. and Samir, M., Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes. J. Control. Release, 100, 111-119 (2004).
5. Ge, Q. H., Zou, Z., Zhi, X. J., Ma, L. L., and Chen, X. H., Pharmacokinetics and absolute bioavailability of breviscapine in beagle dogs (in chinese). Chin. J. Pharm., 34, 618-620 (2003).
6. Giannavola, C., Bucolo, C., Maltese, A., Paolino, D., Vandelli, M. A., Puglisi, G., Lee, V. H. L., and Fresta, M., Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanopheres and effect of PEG coating on ocular drug bioavailability. Pharm. Res., 20, 584-590 (2003).
7. Gulyaev, A., Gelperina, S. E., Skidan, I. N., Antropov, A. S., Kivman, G. Y., and Kreuter, J., Significant transport of doxorubicin into the brain with polysorbate 80 coated nanoparticles. Pharm. Res., 16, 1564-1569 (1999).
8. Gupta, A. K., Madan, S., Majumdar, D. K., and Maitra, A., Ketorolac entrapped in polymeric micelles: preparation, characterization and ocular anti-inflammatory studies. Int. J. Pharm., 209, 1-14 (2000).
9. Hitzman, C. J., Elmquist, W. F., Wattenberg, L. W., and Wiedmann, T. S., Development of a respirable, sustained release microcarrier for 5-fluorouracil I: in vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J. Pharm. Sci., 95, 1114-1126 (2006).
10. Holland, S. J. and Tighe, B. J., Biodegradable polymers. In: Garderton, D. and Jones, T. (Eds.), Advances in pharmaceutical science, vol. 6. New York, Academic Press. pp. 101-164 (1992).
11. Illum, L. and Davis, S. S., Effect of the non-ionic surfactant poloxamer 338 on the fate and deposition of polystyrene microspheres following intravenous administration. J. Pharm. Sci., 72, 1086-1089 (1983).
12. Juliano, R. L., Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions. Adv. Drug Deliv. Rev., 2, 31-54 (1988).
13. Kreuter, J., Nanoparticulate systems for brain delivery of drug. Adv. Drug Deliv. Rev., 47, 65-81 (2001).
14. Kreuter, J., Alyautdin, R. N., Kharkevich, D. A., and Ivanov, A. A., Passage of peptides through the blood-brain barrier with colloidal polymeric particles (nanoparticles). Brain Res., 674, 171-174 (1995).
15. Levy, M. Y. and Benita, S., Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model. Int. J. Pharm., 66, 29-37 (1990).
16. Liu, C., Liu, H. G., Yu, X. L., and Guo, H. C., Advances in studies on Erigeron breviscapus (in chinene). Chinese Wild Plant Resources, 22, 8-11 (2003a).
17. Liu, M. X., Dong, J., Yang, Y. L., Yang, X. L., and Xu, H. B., Research on system of triptolide-loaded poly (D, L-lactic acid) nanoparticles (in chinese). J. Chinese Pharm. Univ., 35, 117-121 (2004).
18. Liu, M. X., Dong, J., Yang, Y. L., Yang, X. L., and Xu, H. B., Anti-inflammatory effects of triptolide loaded poly (d,l-lactic acid) nanoparticles on adjuvant-induced arthritis in rats. J. Ethnopharmacol., 97, 219-225 (2005).
19. Liu, Y. M., Lin, A. H., Chen, H., and Zeng, F. D., Study on pharmacokinetics of scutellarin in rabbits (in chinese). Acta Pharm. Sinica, 38, 775-778 (2003b).
20. Lu, Q., Qu, L. J., Yu, H., Luo, C. M., Han, C. L., and Liu, A. M., Advances in studies on Erigeron breviscapus (in chinese). Chinese Traditional and Herbal Drug, 36, 141-144 (2005).
21. Ma, K., Li, Y. L., and Zhang, Y. P., The clinical application of breviscapine (in chinese). Herald of Medicine, 22, 79-80 (2003).
22. Magenheim, B., Levy, M. Y., and Benita, S., A new in vitro technique for the evaluation of drug release profile from colloidal carriers-ultrafiltration technique at low pressure. Int. J. Pharm., 94, 115-123 (1993).
23. Manjunath, K. and Venkateswarlu, V., Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control. Release, 107, 215-228 (2005).
24. Moghimi, S. M., Pavey K. D., and Hunter A. C., Real-time evidence of surface modification at polystyrene lattices by poloxamine 908 in the presence of serum: in vivo conversion of macrophage-prone nanoparticles to stealth entities by poloxamine 908. FEBS Lett., 547, 177-182 (2003).
25. Muller, R. H. and Goppert, T. M., Protein adsorption patterns on poloxamer-and poloxamine-stabilized solid lipid nanoparticles (SLN). Eur. J. Pharm. Biopharm., 60, 361-372 (2005).
26. Owens, D. E. and Peppas, N. A., Opsonization, biodistration and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm., 307, 93-102 (2006).
27. Redhead, H. M., Davis, S. S., and Illum, L., Drug delivery in poly (lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterization and in vivo evaluation. J. Control. Release, 70, 353-363 (2001).
28. Schroeder, U., Sommerfeld, P., Ulrich, S., and Sabel, B. A., Nanoparticle technology for delivery of drugs across the blood-brain barrier. J. Pharm. Sci., 87, 1305-1307 (1998).
29. Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., and Rudzinski, W. E., Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release, 70, 1-20 (2001).
30. Vega, E., Egea, M. A., Valls, O., Espina, M., and Garcia, M. L., Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. J. Pharm. Sci., 95, 2393-2405 (2006).
31. Win, K. Y. and Feng, S. S., Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials, 26, 2713-2722 (2005).